Apollo Drug Discovery Team

Home  /  Apollo People  /  Dr Paul Hamblin Ph.D
Paul Hamblin


Apollo Therapeutics Project Director

Paul has 18 years’ experience in pharmaceutical drug discovery and development spanning target identification and validation through to early clinical programmes. Paul is a molecular biologist with a degree in Biochemistry and DPhil from the University of Oxford. After completing a short post-doc at the MRC Laboratory of Molecular Biology on V(D)J recombination and leukaemia, he joined GlaxoSmithKline in 1998. Paul has developed his technical experience and leadership skills across multiple therapy areas within Biopharmaceutical and Vaccines Research at GSK. He is named as co-inventor on >25 patents covering 13 candidate and 5 clinical phase assets and has lead five programmes to candidate selection. During the past 10 years, Paul has focused on biopharmaceutical drug discovery having lead antibody design and engineering teams and therapeutic research programmes in Respiratory, Oncology, Neurosciences and Immuno-inflammation. Paul enjoys working with external partners and has lead a number of successful scientific collaborations with academic and commercial partners. These scientific and leadership skills position Paul perfectly as a Project Director at Apollo.

Apollo aims to integrate academic research
and the biopharma industry